Valuation
- Market cap
- 67,844,000
- Revenue TTM
- $0
- Net income TTM
- $-43,440,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 235,800
- Avg volume
- 70,970
- Day's range
- $2.51 – $2.90
- Shares out
- 23,805,000
- Stochastic %K
- 25%
- Beta
- 0.42
- Analysts
- Strong Sell
- Price target
- $17.67
Company profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular ret...
Show more
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 249 2727
- Website
- https://kalaristx.com
- Address
- 400 Connell Drive, Suite 5500 Berkeley Heights, Berkeley Heights, United States
Latest news
No headlines yet.
